Glioma Diagnosis Market Share Research Report Analysis Forecast, 2019 – 2027

Admin

5 years ago

Glioma: A Common Type of Brain Tumor That can be Fatal

Glioma is a common type of tumor originating in the brain, which is formed in glial cells. Glial cells are cells in the brain, which surround and support neurons in the brain including astrocytes, oligodendrocytes, and ependymal cells.
Glioma can affect functioning of the brain and it can be fatal, depending on its location and severity of tumor

Glioma is of different types: astrocytomas, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas
Headache; seizures; numbness; weakness in the arms, the face, or the legs; and personality changes are some of the major symptoms observed in patients with glioma
Risk factors for the development of glioma range from old age (more common in adults between 45-65 years of age) and radiation exposure to family history of glioma
Various diagnostic methods are available for detection of glioma. Depending on severity of the disease, different types of treatments or therapies are suggested to patients.

Key Drivers and Restraints of Global Glioma Diagnosis Market

Advancements in brain tumor diagnosis and growing prevalence of brain cancer are some of the major factors fueling the global glioma diagnosis market
For instance, as per the American Society of Clinical Oncology (ASCO), around 23,820 adults in the U.S. were diagnosed with primary cancerous tumors of the brain and the spinal cord in 2018. Brain tumors accounted for 85% to 90% of all primary CNS (central nervous system) tumors in the country in the year.
Combination of most advanced diagnostic scanning techniques and rising awareness regarding various types of brain tumors are some of the major factors responsible for growth of the global glioma diagnosis market
Moreover, growing human exposure to radiations in recent times is leading to high rate of incidence of the brain cancer. This is another factor driving the global glioma diagnosis market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75851′

Higher Costs of Diagnosis Hamper Global Market

Cost of diagnosis of the brain tumor is very high and it is unaffordable for patients in several developing countries. This high cost can adversely impact the global glioma diagnosis market.
Regrowth of tumor after treatment and surgery in several cases and adverse effects of chemotherapy are also projected to hamper the global market for glioma diagnosis during the forecast period

Primary Tumor Type Segment Dominates Global Market

Based on tumor type, the global glioma diagnosis market can be bifurcated into primary tumors and secondary tumors
The primary tumors segment can be sub-divided into astrocytomas, ependymomas, brain stem gliomas, oligodendrogliomas, mixed gliomas, and others
The primary tumors segment dominates the global glioma diagnosis market, as primary tumors are more prevalent across the world

Low-grade Gliomas a Promising Grade Segment

In terms of grade, the global glioma diagnosis market can be segmented into low-grade gliomas, high-grade gliomas, and recurrent high-grade gliomas
Low-grade gliomas is expected to be the most lucrative segment in the next few years, due to availability of more treatment options and early detection of tumors of low grade

PET Scan Segment Witnesses Strong Growth

In terms of diagnosis test, the global glioma diagnosis market can be classified into neurological exams, computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, biopsy, electroencephalography (EEG), and others
The MRI segment accounted for a major market share in 2018. The PET scans segment is estimated to expand at a high CAGR during the forecast period, owing to better sensitivity and higher rate of precision offered by MRI for glioma diagnosis

Hospitals & Clinics a Dominant End-user Segment

Based on end-user, the global glioma diagnosis market can be segmented into hospitals & clinics, diagnostic imaging centers, cancer research institutes, and others
The hospitals & clinics segment dominated the global glioma diagnosis market in 2018, owing to the large number of admissions of cancer patients at hospitals and availability of advanced equipment at hospitals and clinics

North America to Lead Global Market for Glioma Diagnosis

In terms of region, the global glioma diagnosis market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America dominated the global glioma diagnosis market in 2018, due to high prevalence of brain tumor in the region, growing radiation exposure, and availability of advanced diagnostic devices in the region
Asia Pacific is likely to be a more promising market for glioma diagnosis in the next few years, due to large geriatric population, the large number of patients with cancer, and rise in awareness regarding diseases and their diagnosis in the region. As per a study published by NCBI in September 2011, the rate of prevalence of primary brain tumors in China was 24.56 per 100,000 people in 2006.

Key Manufacturers Operating in Global Market

Key manufacturers operating in the global glioma diagnosis market are:

Global Glioma Diagnosis Market: Research Scope

Global Glioma Diagnosis Market, by Tumor Type

Global Glioma Diagnosis Market, by Grade

Global Glioma Diagnosis Market, by Diagnosis Test

Global Glioma Diagnosis Market, by End-user

Global Glioma Diagnosis Market, by Region

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa